{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:11:39Z","timestamp":1778857899443,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"DOI":"10.7759\/cureus.108896","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:29:11Z","timestamp":1778855351000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug-Induced Liver Injury Following Co-ingestion of Veterinary Fenbendazole and Ivermectin for Prostate Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Grace E","family":"Powderly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiley","family":"Hassevoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Loy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Balonier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Sievers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17197","article-title":"Oral fenbendazole for cancer therapy in humans and animals","volume":"44","author":"Nguyen J","year":"2024","unstructured":"Nguyen J, Nguyen TQ, Han BO, Hoang BX. Oral fenbendazole for cancer therapy in humans and animals. Anticancer Res. 2024, 44:3725-35. 10.21873\/anticanres.17197","journal-title":"Anticancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.58803\/jlar.v1i1.11","article-title":"The anticancer potential of ivermectin: mechanisms of action and therapeutic implications","volume":"25","author":"Lotfalizadeh N","year":"2022","unstructured":"Lotfalizadeh N, Gharib A, Hajjafari A, et al.. The anticancer potential of ivermectin: mechanisms of action and therapeutic implications. Lab Anim Res. 2022, 25:52-9. 10.58803\/jlar.v1i1.11","journal-title":"Lab Anim Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bea.2025.100144","article-title":"Exploring therapeutic strategies for androgen-independent prostate cancer using a magnetic coculture platform","volume":"2","author":"Chavali A","year":"2025","unstructured":"Chavali A, Fitzwilliams G, Germain A, Khuon S, Kim YT. Exploring therapeutic strategies for androgen-independent prostate cancer using a magnetic coculture platform. Biomed Eng Adv. 2025, 2:100144. 10.1016\/j.bea.2025.100144","journal-title":"Biomed Eng Adv"},{"key":"ref4","unstructured":"Stromectol (Ivermectin). Package insert. Merck & Co Inc. (2009). Accessed. April 25, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050742s026lbl.pdf."},{"key":"ref5","unstructured":"U.S. Food and Drug Administration. FDA approves first generic fenbendazole oral suspension dewormer for beef and dairy cattle, goats. (2023). Accessed. March 28, 2026: https:\/\/www.fda.gov\/animal-veterinary\/cvm-updates\/fda-approves-first-generic-fenbendazole-oral-suspension-dewormer-be...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-021-03025-z","article-title":"Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects","volume":"95","author":"Rendic SP","year":"2021","unstructured":"Rendic SP. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects. Arch Toxicol. 2021, 95:1535-46. 10.1007\/s00204-021-03025-z","journal-title":"Arch Toxicol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00843-13","article-title":"CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems","volume":"57","author":"Wu Z","year":"2013","unstructured":"Wu Z, Lee D, Joo J, et al.. CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013, 57:5448-56. 10.1128\/AAC.00843-13","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001150684.12205.aa","article-title":"S5806 drug-induced liver injury from off-label fenbendazole use in metastatic breast cancer: a case report","volume":"120","author":"Chaturvedi M","year":"2025","unstructured":"Chaturvedi M, Saba L, Amroze A, Zhang J, McConville M, Selner G, Sutaria J. S5806 drug-induced liver injury from off-label fenbendazole use in metastatic breast cancer: a case report. Am J Gastroenterol. 2025, 120:38. 10.14309\/01.ajg.0001150684.12205.aa","journal-title":"Am J Gastroenterol"},{"key":"ref9","article-title":"Ivermectin","year":"2021","unstructured":"Ivermectin. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2021."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000868300.70244.f2","article-title":"S2915 presidential poster award. A case report of ivermectin-induced liver failure","volume":"117","author":"Sidhu SB","year":"2022","unstructured":"Sidhu SB, Tang IB, Jain S, Shalini S, Kassim T, Rangray R. S2915 presidential poster award. A case report of ivermectin-induced liver failure. Am J Gastroenterol. 2022, 117:e1898. 10.14309\/01.ajg.0000868300.70244.f2","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.02.003","article-title":"First case of ivermectin-induced severe hepatitis","volume":"100","author":"Veit O","year":"2006","unstructured":"Veit O, Beck B, Steuerwald M, Hatz C. First case of ivermectin-induced severe hepatitis. Trans R Soc Trop Med Hyg. 2006, 100:795-7. 10.1016\/j.trstmh.2006.02.003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2023.v113i6.624","article-title":"Ivermectin drug induced liver injury","volume":"113","author":"Sonderup M","year":"2023","unstructured":"Sonderup M, Mudini W, Spearman W. Ivermectin drug induced liver injury. S Afr Med J. 2023, 113:24-5. 10.7196\/SAMJ.2023.v113i6.624","journal-title":"S Afr Med J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.818","article-title":"A single institutional experience on patterns of ivermectin and fenbendazole use among patients with gastrointestinal cancers","volume":"44","author":"Olutayo E","year":"2026","unstructured":"Olutayo E, Phan MV, Willis J, Hu ZI. A single institutional experience on patterns of ivermectin and fenbendazole use among patients with gastrointestinal cancers. J Clin Oncol. 2026, 44:818. 10.1200\/JCO.2026.44.2_suppl.818","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2114907","article-title":"Toxic effects from ivermectin use associated with prevention and treatment of Covid-19","volume":"385","author":"Temple C","year":"2021","unstructured":"Temple C, Hoang R, Hendrickson RG. Toxic effects from ivermectin use associated with prevention and treatment of Covid-19. N Engl J Med. 2021, 385:2197-8. 10.1056\/NEJMc2114907","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06948-6","article-title":"Increase in outpatient ivermectin dispensing in the US during the COVID-19 pandemic: a cross-sectional analysis","volume":"36","author":"Lind JN","year":"2021","unstructured":"Lind JN, Lovegrove MC, Geller AI, Uyeki TM, Datta SD, Budnitz DS. Increase in outpatient ivermectin dispensing in the US during the COVID-19 pandemic: a cross-sectional analysis. J Gen Intern Med. 2021, 36:2909-11. 10.1007\/s11606-021-06948-6","journal-title":"J Gen Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001354","article-title":"Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication, fenbendazole","volume":"11","author":"Thakurdesai A","year":"2024","unstructured":"Thakurdesai A, Rivera-Matos L, Nagra N, Busch B, Mais DD, Cave MC. Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication, fenbendazole. ACG Case Rep J. 2024, 11:e01354. 10.14309\/crj.0000000000001354","journal-title":"ACG Case Rep J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.201199","article-title":"Susceptibility to misinformation about COVID-19 around the world","volume":"7","author":"Roozenbeek J","year":"2020","unstructured":"Roozenbeek J, Schneider CR, Dryhurst S, et al.. Susceptibility to misinformation about COVID-19 around the world. R Soc Open Sci. 2020, 7:201199. 10.1098\/rsos.201199","journal-title":"R Soc Open Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.09.014","article-title":"Social media and its impact on health care","volume":"128","author":"Patrick M","year":"2022","unstructured":"Patrick M, Venkatesh RD, Stukus DR. Social media and its impact on health care. Ann Allergy Asthma Immunol. 2022, 128:139-45. 10.1016\/j.anai.2021.09.014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09118-6","article-title":"Online misleading information about women\u2019s reproductive health: a narrative review","volume":"40","author":"John JN","year":"2025","unstructured":"John JN, Gorman S, Scales D, Gorman J. Online misleading information about women\u2019s reproductive health: a narrative review. J Gen Intern Med. 2025, 40:1123-31. 10.1007\/s11606-024-09118-6","journal-title":"J Gen Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31876","article-title":"The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient","volume":"72","author":"Gilene S","year":"2025","unstructured":"Gilene S, Haacker L, Rutan H, Pressey JG. The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient. Pediatr Blood Cancer. 2025, 72:e31876. 10.1002\/pbc.31876","journal-title":"Pediatr Blood Cancer"},{"key":"ref21","unstructured":"U.S. Food and Drug Administration. Ivermectin. (2023). Accessed. March 28, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050742s022lbl.pdf."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan G","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015, 17:14. 10.3390\/ijms17010014","journal-title":"Int J Mol Sci"},{"key":"ref23","article-title":"Drug-induced liver injury","volume":"6","author":"David S","year":"2010","unstructured":"David S, Hamilton JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev. 2010, 6:73-80.","journal-title":"US Gastroenterol Hepatol Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.027","article-title":"Drug-induced liver injury: morbidity, mortality, and Hy's law","volume":"147","author":"Regev A","year":"2014","unstructured":"Regev A, Bj\u00f6rnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy's law. Gastroenterology. 2014, 147:20-4. 10.1053\/j.gastro.2014.05.027","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives","volume":"146","author":"Fontana RJ","year":"2014","unstructured":"Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014, 146:914-28. 10.1053\/j.gastro.2013.12.032","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062954","article-title":"Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges","volume":"22","author":"Jee A","year":"2021","unstructured":"Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges. Int J Mol Sci. 2021, 22:2954. 10.3390\/ijms22062954","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e75","article-title":"Anthelmintics as potential anti-cancer drugs?","volume":"35","author":"Heo DS","year":"2020","unstructured":"Heo DS. Anthelmintics as potential anti-cancer drugs?. J Korean Med Sci. 2020, 35:e75. 10.3346\/jkms.2020.35.e75","journal-title":"J Korean Med Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478304-drug-induced-liver-injury-following-co-ingestion-of-veterinary-fenbendazole-and-ivermectin-for-prostate-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:29:13Z","timestamp":1778855353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478304-drug-induced-liver-injury-following-co-ingestion-of-veterinary-fenbendazole-and-ivermectin-for-prostate-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.108896","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}